Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 107

1.

Re-challenge with pemetrexed in advanced mesothelioma: a multi-institutional experience.

Bearz A, Talamini R, Rossoni G, Santo A, de Pangher V, Fasola G, Rosetti F, Favaretto A, Gregorc V, Berretta M, Santarossa S, Berto E, Tirelli U.

BMC Res Notes. 2012 Sep 3;5:482. doi: 10.1186/1756-0500-5-482.

2.

Retreatment with pemetrexed-based chemotherapy in patients with malignant pleural mesothelioma.

Ceresoli GL, Zucali PA, De Vincenzo F, Gianoncelli L, Simonelli M, Lorenzi E, Ripa C, Giordano L, Santoro A.

Lung Cancer. 2011 Apr;72(1):73-7. doi: 10.1016/j.lungcan.2010.12.004. Epub 2011 Jan 8.

PMID:
21216487
3.

Phase III trial of pemetrexed plus best supportive care compared with best supportive care in previously treated patients with advanced malignant pleural mesothelioma.

Jassem J, Ramlau R, Santoro A, Schuette W, Chemaissani A, Hong S, Blatter J, Adachi S, Hanauske A, Manegold C.

J Clin Oncol. 2008 Apr 1;26(10):1698-704. doi: 10.1200/JCO.2006.09.9887.

4.

Pemetrexed re-challenge in pleural malignant mesothelioma: an option for a subset of patients initially treated with pemetrexed-platinum doublets in the first-line setting?

Zalcman G, Bergot E, Lechapt E.

Lung Cancer. 2011 Apr;72(1):1-2. doi: 10.1016/j.lungcan.2010.12.021. Epub 2011 Jan 28. No abstract available.

PMID:
21277041
5.

Pemetrexed in malignant pleural mesothelioma.

Hazarika M, White RM Jr, Booth BP, Wang YC, Ham DY, Liang CY, Rahman A, Gobburu JV, Li N, Sridhara R, Morse DE, Lostritto R, Garvey P, Johnson JR, Pazdur R.

Clin Cancer Res. 2005 Feb 1;11(3):982-92.

6.

Second-line treatment for malignant pleural mesothelioma.

Ceresoli GL, Zucali PA, Gianoncelli L, Lorenzi E, Santoro A.

Cancer Treat Rev. 2010 Feb;36(1):24-32. doi: 10.1016/j.ctrv.2009.09.003. Epub 2009 Oct 29. Review.

PMID:
19879055
7.

Second-line chemotherapy in malignant pleural mesothelioma: results of a retrospective multicenter survey.

Zucali PA, Simonelli M, Michetti G, Tiseo M, Ceresoli GL, Collovà E, Follador A, Lo Dico M, Moretti A, De Vincenzo F, Lorenzi E, Perrino M, Giordano L, Farina G, Santoro A, Garassino M.

Lung Cancer. 2012 Mar;75(3):360-7. doi: 10.1016/j.lungcan.2011.08.011. Epub 2011 Sep 19.

PMID:
21937142
8.

Pemetrexed: new drug. Pleural mesothelioma: a first encouraging trial.

[No authors listed]

Prescrire Int. 2005 Dec;14(80):212-4.

PMID:
16400741
9.

Pemetrexed for malignant pleural mesothelioma: Is it a standard second-line therapy?

Tamura K, Fujiwara Y.

Asia Pac J Clin Oncol. 2010 Dec;6(4):248-50. doi: 10.1111/j.1743-7563.2010.01362.x. No abstract available.

PMID:
21114772
10.

Vinorelbine in pemetrexed-pretreated patients with malignant pleural mesothelioma.

Zucali PA, Perrino M, Lorenzi E, Ceresoli GL, De Vincenzo F, Simonelli M, Gianoncelli L, De Sanctis R, Giordano L, Santoro A.

Lung Cancer. 2014 Jun;84(3):265-70. doi: 10.1016/j.lungcan.2013.11.011. Epub 2013 Nov 20.

PMID:
24321581
11.

Pemetrexed: a multitargeted antifolate.

Rollins KD, Lindley C.

Clin Ther. 2005 Sep;27(9):1343-82. Review.

PMID:
16291410
12.

Pemetrexed as second-line treatment in malignant pleural mesothelioma after platinum-based first-line treatment.

Sørensen JB, Sundstrøm S, Perell K, Thielsen AK.

J Thorac Oncol. 2007 Feb;2(2):147-52.

13.

Pemetrexed disodium for the treatment of malignant pleural mesothelioma: a systematic review and economic evaluation.

Dundar Y, Bagust A, Dickson R, Dodd S, Green J, Haycox A, Hill R, McLeod C, Walley T.

Health Technol Assess. 2007 Jan;11(1):1-90. Review.

14.

Pemetrexed in malignant pleural mesothelioma and the clinical outcome.

Knuuttila A, Salomaa ER, Saikkonen S, Hurme S, Salo J.

Clin Respir J. 2012 Apr;6(2):96-103. doi: 10.1111/j.1752-699X.2011.00252.x. Epub 2011 Jul 6.

PMID:
21651743
15.

Pemetrexed maintenance therapy in patients with malignant pleural mesothelioma.

van den Bogaert DP, Pouw EM, van Wijhe G, Vernhout RM, Surmont VF, Hoogsteden HC, van Klaveren RJ.

J Thorac Oncol. 2006 Jan;1(1):25-30.

16.

Systemic treatments for mesothelioma: standard and novel.

Kindler HL.

Curr Treat Options Oncol. 2008 Jun;9(2-3):171-9. doi: 10.1007/s11864-008-0071-3. Epub 2008 Sep 3. Review.

17.

Can pemetrexed help in malignant mesothelioma?

[No authors listed]

Drug Ther Bull. 2006 Oct;44(10):77-80. Review.

PMID:
17067119
18.

Pemetrexed in the treatment of malignant mesothelioma: results from an expanded access program in Germany.

Reck M, Stahel RA, von Pawel J, Karthaus M, Korfee S, Serke M, Schuette WH, Eschbach C, Fink TH, Leschinger MI, Manegold C.

Respir Med. 2010 Jan;104(1):142-8. doi: 10.1016/j.rmed.2009.07.019. Epub 2009 Oct 8.

19.

The value of pemetrexed for the treatment of malignant pleural mesothelioma: a comprehensive review.

Boons CC, VAN Tulder MW, Burgers JA, Beckeringh JJ, Wagner C, Hugtenburg JG.

Anticancer Res. 2013 Sep;33(9):3553-61. Review.

PMID:
24023280
20.
Items per page

Supplemental Content

Write to the Help Desk